Literature DB >> 20594843

A novel, broad-spectrum anticancer compound containing the imidazo[4,5-e][1,3]diazepine ring system.

Min Xie1, Ravi K Ujjinamatada, Mariola Sadowska, Rena G Lapidus, Martin J Edelman, Ramachandra S Hosmane.   

Abstract

Synthesis and broad-spectrum anticancer activity of a novel heterocyclic compound 1 containing the title imidazo[4,5-e][1,3]diazepine ring system have been reported. The compound shows potent in vitro antitumor activity with low micromolar IC(50)'s against prostate, lung, breast, and ovarian cancer cell lines tested. The long alkyl chain attached to the six-position of the heterocyclic ring of 1 appears to be necessary for the observed biological activity. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20594843      PMCID: PMC2905507          DOI: 10.1016/j.bmcl.2010.06.061

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

Review 1.  Chemoprevention of cancer.

Authors:  M B Sporn; N Suh
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

Review 2.  Advances in mitotic inhibitors for cancer treatment.

Authors:  Ning Jiang; Xiaoxing Wang; Yali Yang; Wei Dai
Journal:  Mini Rev Med Chem       Date:  2006-08       Impact factor: 3.862

Review 3.  Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer.

Authors:  V Craig Jordan
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 4.  Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.

Authors:  Luca Toschi; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 5.  Do beta-tubulin mutations have a role in resistance to chemotherapy?

Authors:  Helen K Berrieman; Michael J Lind; Lynn Cawkwell
Journal:  Lancet Oncol       Date:  2004-03       Impact factor: 41.316

Review 6.  Novel pharmacological approaches in the treatment of breast cancer.

Authors:  Rita Nahta; Gabriel N Hortobagyi; Francisco J Esteva
Journal:  Expert Opin Investig Drugs       Date:  2003-06       Impact factor: 6.206

Review 7.  Smart drugs: tyrosine kinase inhibitors in cancer therapy.

Authors:  Laura K Shawver; Dennis Slamon; Axel Ullrich
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

8.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

9.  Rofecoxib reduces polyp recurrence in familial polyposis.

Authors:  A Hallak; L Alon-Baron; R Shamir; M Moshkowitz; B Bulvik; E Brazowski; Z Halpern; N Arber
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

10.  Small molecule tyrosine kinase inhibitors in pancreatic cancer.

Authors:  Sachin Gupta; Bassel F El-Rayes
Journal:  Biologics       Date:  2008-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.